Serological Responses of Coyotes to Two Commercial
Rabies Vaccines by Knowlton, Frederick F. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
USDA National Wildlife Research Center - Staff 
Publications 
U.S. Department of Agriculture: Animal and 
Plant Health Inspection Service 
2001 
Serological Responses of Coyotes to Two Commercial Rabies 
Vaccines 
Frederick F. Knowlton 
Utah State University, knowlton@cc.usu.edu 
Marianna Roetto 
National Wildlife Research Center 
Deborah Briggs 
Kansas State University 
Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc 
 Part of the Environmental Sciences Commons 
Knowlton, Frederick F.; Roetto, Marianna; and Briggs, Deborah, "Serological Responses of Coyotes to Two 
Commercial Rabies Vaccines" (2001). USDA National Wildlife Research Center - Staff Publications. 1047. 
https://digitalcommons.unl.edu/icwdm_usdanwrc/1047 
This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health 
Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA 
National Wildlife Research Center - Staff Publications by an authorized administrator of DigitalCommons@University 
of Nebraska - Lincoln. 
798
Journal of Wildlife Diseases, 37(4), 2001, pp. 798–802
Serological Responses of Coyotes to Two Commercial
Rabies Vaccines
Frederick F. Knowlton,1,4 Marianna Roetto,2 and Deborah Briggs,3 1USDA/APHIS/WS, National Wildlife Re-
search Center, Utah State University, Logan, Utah 84322-5295, USA; 2P.O. Box 3653, Edgewood, New Mexico
87015-3653, USA; 3Veterinary Diagnostic Laboratory, Veterinary Clinical Science Building, Kansas State Uni-
versity, Manhattan, Kansas 66506-5600, USA; 4Corresponding author (e-mail: knowlton@cc.usu.edu).
ABSTRACT: Between August 1993 and Sep-
tember 1994 we documented serological re-
sponses of coyotes (Canis latrans) vaccinated
with two commercial rabies vaccines licensed
for use in domestic dogs. Serologic responses
were documented by testing for rabies virus
neutralizing antibodies with the rapid fluores-
cent focus inhibition test (RFFIT) at 30, 90,
180, 270, and 365 days post-vaccination. All
coyotes vaccinated with Imrab 3 (Rhone-Mer-
ieux, Inc.), and 75% of those vaccinated with
Dura-Rab 3 (Immunovet, Inc.) seroconverted,
as evidenced by the presence of antirabies an-
tibody titers 1:5 in one or more of the five
post-vaccination samples. The percent of coy-
otes showing a titer 1:5 was generally greater
and titer levels appeared higher and more per-
sistent among animals vaccinated with Imrab
3 than Dura-Rab 3. Presence of titers via
RFFIT tests demonstrates the antibodies pro-
duced in coyotes by these rabies vaccines func-
tionally bind and neutralize rabies virus in vitro,
but these results do not constitute a demon-
stration of protection required for licensure for
use in coyotes.
Key words: Canis latrans, coyote, immu-
nization, rabies, vaccination.
Rabies, an infectious disease of mam-
mals, is typically fatal once clinical symp-
toms are evident. Consequently, disease
management concentrates on limiting ex-
posure and immunization through vacci-
nation (Bunn, 1991). Currently, only killed
virus rabies vaccines, which are generally
less immunogenic than modified live vac-
cines, are licensed for use in the United
States. Some manufacturers incorporate
adjuvants (compounds that increase the
antigenicity) into vaccines to provide high-
er and more sustained titers (Tizard, 1996;
pp. 275–277).
Susceptibility and immunologic re-
sponse to rabies virus differs among spe-
cies (Dreesen, 1999). As a result, rabies
vaccines undergo stringent testing for ef-
ficacy and safety in each species for which
they are licensed (Anonymous, 1992). Be-
cause efficacy of rabies vaccines is deter-
mined only through costly live virus chal-
lenge tests, vaccine manufacturers concen-
trate licensure efforts on species for which
vaccination offers potential economic re-
turn (i.e., domestic pets and farm animals).
Despite lack of licensed rabies vaccines for
most wildlife species, many zoos, wildlife
parks, and research institutions routinely
vaccinate wildlife against rabies in the
hope of conferring some protection for
captive animals and personnel (Jenkins et
al., 2001), but not in lieu of ‘‘appropriate
public health activities that protect hu-
mans.’’
The Logan Field Station of the National
Wildlife Research Center (Logan, Utah,
USA) maintains a colony of captive coyotes
(Canis latrans) for research purposes.
Health concerns for animal and personnel
dictate a schedule of vaccination against
common canine and zoonotic pathogens,
including rabies. Coyotes in the colony re-
ceive an annual vaccination with a com-
mercial rabies vaccine approved for use in
domestic dogs with the understanding the
vaccine is not licensed for use in coyotes
and cannot be considered legally protec-
tive in this species. Live virus challenge
studies are not within the purview of the
Logan facility, but we were able to evalu-
ate the induction and persistence of rabies
virus neutralizing antibodies among cap-
tive coyotes over a 1 yr period related to
use of two commercial rabies vaccines li-
censed for use in domestic dogs.
We started the study in August 1993
with 58 hand-reared coyotes (25 females
and 33 males) about 4 mo of age from the
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captive colony. They were penned in
groups of three until 8-mo-old; thereafter
they were housed in individual kennels or
as male-female pairs in 0.1-ha enclosures.
They were maintained throughout the
study on a food ration prepared for the
local fur industry (Furbreeders Agricultur-
al Cooperative, Logan, Utah) and had ac-
cess to water ad libitum. Upon completion
of the study in September 1994, coyotes
were returned to the colony.
We evaluated two commercial killed-ra-
bies vaccines. One, Dura-Rab 3 (Immuno
Vet, Inc., Tampa, Florida, USA; U.S. Vet-
erinary License #302A, Serial #379, Expi-
ration 24Jan94), was a non-adjuvanted vac-
cine licensed for intramuscular administra-
tion. The other, Imrab 3 (Rhone-Mer-
ieux, Inc., Athens, Georgia, USA; U.S.
Veterinary License #298, Serial #12116,
Expiration 10Feb96), was an adjuvanted
(aluminium hydroxide) vaccine licensed
for intramuscular or subcutaneous admin-
istration. Venders donating the vaccines
did not provide potency information for
their respective products, although they
were aware of our study intentions.
At the start of the study, coyotes were
stratified by genetic background (i.e., lit-
ter) and sex and then randomly assigned
to one of three treatment groups: (1) in-
tramuscular injection of Dura-Rab 3; (2)
intramuscular injection of Imrab 3; and
(3) subcutaneous injection of Imrab 3.
They were serologically tested via rapid
fluorescent focus inhibition test (RFFIT)
to ensure they were negative for rabies vi-
rus neutralizing antibody. Vaccines were
then administered as per manufacturers
label instructions using sterile 3 ml syrin-
ges and 22 gauge  2.5 cm needles. Intra-
muscular vaccination was by deep injec-
tion at a single location in caudal thigh
musculature, while subcutaneous vaccina-
tion involved injection in the intrascapular
region. Sera collections were conducted
prior to treatment and on days 30, 90, 180,
270 and 365 post-vaccination. Coyotes
were physically or chemically (i.e., intra-
muscular injection of 100 mg ketamine hy-
drochloride and 1 mg acepromazine ma-
leate) restrained and blood (7 ml/animal)
obtained from the cephalic vein of each
subject using evacuated collection tubes.
Tubes were allowed to stand for 1 to 4 hr
at room temperature prior to centrifuga-
tion and aspiration of the sera. Sera sam-
ples were aliquotted into 2-ml micro-cen-
trifuge tubes and maintained at 70 C for
1 to 3 days prior to shipment. Samples
were shipped overnight on dry ice in in-
sulated containers to Kansas State Univer-
sity (Manhattan, Kansas, USA) where they
were stored at 70 C until analyzed. Ra-
bies virus antibody titers were determined
at the Veterinary Diagnostic Laboratory
(Kansas State University) via RFFIT. We
used analysis of variance (ANOVA) to
compare overall performance of the two
vaccines (P  0.05) followed by a post hoc
use of Fisher’s least significant difference
(LSD) multiple comparison test to assess
which individual comparisons were differ-
ent (P  0.05). Fourteen wk after this
study concluded, many of these coyotes
were incorporated into another study in-
volving an oral rabies vaccine. Anamnestic
responses to re-exposure to rabies antigen
in that study provided some additional in-
formation relevant to our study.
Serologic testing prior to vaccinations
revealed titers of 1:5 (considered nega-
tive) for all study coyotes (Table 1). Over-
all, 53 of the 58 coyotes (91%) are known
to have seroconverted, as demonstrated by
rabies specific titers 1:5 via RFFIT at
least once among the five sampling periods
during the ensuing year (Table 1). Three
additional animals, for which rabies anti-
bodies were not detected, showed an an-
amnestic response to an oral rabies vaccine
after this study was concluded, suggesting
memory immune cells to rabies antigen
were present (Van Kampen, 1999).
At 30 days post-vaccination, all 39 coy-
otes receiving Imrab 3, regardless of
route of administration, and 13/19 (68%)
of coyotes receiving Dura-Rab 3 showed
positive titers (Table 1). Absence of de-
tectable rabies antibody in 6 coyotes in the
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latter treatment group on day 30 could be
related to: (1) improper administration of
vaccine; (2) use of an impotent vaccine; (3)
failure of the immune system; or (4) fail-
ure to detect an early immunologic re-
sponse in conjunction with a rapid dissi-
pation of antibodies. Improper vaccine ad-
ministration seems unlikely since all vac-
cinations were given by the same
individual via standard protocols, with all
detection failures occurring in the same
treatment. An impotent vaccine seems un-
likely since it came from a common lot and
was maintained under appropriate and
identical storage conditions. Failure of the
immune system to function (poor respond-
ers) in these individuals is possible, al-
though seemingly unlikely. Extrinsic fac-
tors relating to antigen quantity, quality,
and presentation of the vaccine could also
contribute to immunologic failure but this
seems unlikely.
The six coyotes in the Dura-Rab 3
treatment that were not seropositive on
day 30 post-vaccination may have experi-
enced a rise and fall in anti-rabies antibody
prior to day 30. If this occurred, the im-
munologic response may have been sub-
optimal and it is conjectural whether these
animals were adequately protected in the
event of subsequent exposure to rabies vi-
rus. It should be noted that four of the six
gave other indications of seroconverting;
one that did not have titers on days 30, 90,
or 180, was seropositive on days 270 and
365, and three of four used in the oral ra-
bies protocol after this study concluded,
showed an anamnestic response, suggest-
ing memory immune cells to rabies anti-
gen were present. At 365 days post-vacci-
nation, 20 of 20 (100%) coyotes receiving
Imrab 3 intramuscularly, 16 of 19 (84%)
coyotes receiving Imrab 3 subcutaneous-
ly, and eight of 19 (42%) coyotes receiving
Dura-Rab 3 intramuscularly were sero-
positive for anti-rabies antibody (Table 1).
Overall, ANOVA revealed a significant
difference in mean titers among the three
treatments (F  11.64, df  55, P 
0.001). Post hoc use of Fisher’s LSD test
suggests titers associated with intramus-
cular injections of Imrab 3 were consis-
tently higher than Durab-3 injected sim-
ilarly. Initially, differences among the
treatments were substantive, but they
waned with advancing time (Table 1). A
decrease in circulating antibody can be ex-
pected as the protective function of the
immune system shifts from production of
circulating antibody to reliance on mem-
ory immune cells to combat exposures to
rabies antigen. Superficially, coyotes re-
ceiving Imrab 3 appeared to maintain
higher and more persistent titers through-
out the study (Table 1). This likely reflects
presence of an adjuvant in Imrab 3, (Ti-
zard, 1996) but might also relate to other
aspects of vaccine composition.
Although differences were not statisti-
cally significant (P  0.05), coyotes vacci-
nated with Imrab 3 intramuscularly ap-
peared to have higher titers compared to
those vaccinated subcutaneously (Table 1).
Similarly, while males seemed to have (1)
a greater percent of subjects with rabies
antibody titers; (2) higher average titers;
and (3) the highest individual titers (Table
1) compared to females, differences were
not significant (P  0.05).
Maintenance of high, persistent titers
may provide a measure of protective as-
surance, but does not necessarily identify
vaccines as superior products because pro-
tection against disease also includes the
ability to produce memory immune cells
(Artois et al., 1993). These could result in
anamnestic responses, as evidenced here
by 4 animals that showed titers 1:5 (con-
sidered negative) during one sampling but
had substantial titers during a subsequent
sampling, and at least eight animals that
more than doubled antibody levels be-
tween post-vaccination samples. In addi-
tion, three animals for which we never de-
tected a titer showed an anamnestic re-
sponse following exposure to an oral rabies
vaccine after this study was over. Although
some animals may be protected at low or
non-detectable titer levels, Bunn et al.
(1984) showed a correlation between high-
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er antibody titers and higher survival rates
of dogs during live virus challenge. The
level of antibody necessary to confer pro-
tection in the coyote is not known and can
only be determined through controlled
challenge studies utilizing a virulent rabies
virus.
Efforts to compare titers in coyotes and
dogs receiving the same vaccine are sub-
jective because titer information collected
by manufacturers is proprietary and not
readily available. In addition, there are sig-
nificant differences in species susceptibil-
ity to various strains of rabies virus, with
titers that are protective in one species
sometimes failing to protect another. Data
on dogs provided by manufacturers sug-
gests the titers among coyotes immunized
with Dura-Rab 3 were lower and less
persistent than among dogs vaccinated
with the same product. However, titers ap-
peared similar between coyotes and dogs
vaccinated with Imrab 3.
One goal of vaccination is to protect an-
imals from disease by producing antibod-
ies that effectively bind and neutralize a
pathogen. The use of RFFIT in this study
essentially demonstrates this function.
RFFIT titers are determined by incubat-
ing sera dilutions with live rabies virus
with the antibody binding and neutralizing
the virus providing a quantitative assay of
the sample. The resulting titers demon-
strate the antibody produced was function-
al in vitro.
Our study demonstrated that coyotes
can produce rabies specific antibody in re-
sponse to vaccination with two commercial
rabies vaccines licensed for use in domes-
tic dogs. Furthermore, the antibodies pro-
duced were capable of binding and neu-
tralizing live rabies virus in vitro. While it
is reasonable to infer a measure of protec-
tion was conferred to coyotes receiving
these vaccines, confirmation of such pro-
tection can only be obtained through live
rabies challenge tests. Research on other
species suggests that high, persistent titers
are usually protective for most individuals.
We are grateful to the staff and students
associated with the Logan Field Station of
the National Wildlife Research Center
(NWRC) for their assistance in handling
animals and taking blood samples. This
study was conducted under the guidance
of the NWRC animal care and use com-
mittee under protocol QA-345. The Vet-
erinary Diagnostic Laboratory at the Kan-
sas State University supported the anti-
body assay aspects of the study. Rhone-
Mereieux, Inc. (now Merial, Limited) and
Immunovet, Inc. graciously donated the
vaccines for this study. Identification and
use of trade names and products does not
imply endorsement by the federal govern-
ment.
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